Get the Stockscreener App
0.95
1.55%
-0.015
After Hours:
1.00
0.05
+5.26%
Vyne Therapeutics Inc Stock (VYNE) Forecast
The Vyne Therapeutics Inc (VYNE) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $40.89, representing a +4,204% increase from the current price of $0.95. The highest analyst price target is $75.15, and the lowest is $6.6218.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month VYNE Price Target
Average 97.84
(+10,199% Upside)
Is Vyne Therapeutics Inc (VYNE) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 25.56 | Buy |
| STOCH(9,6) | 6.8363 | Buy |
| STOCHRSI(14) | 3.2547 | Buy |
| MACD(12,26) | -0.1608 | Sell |
| ADX(14) | 37.23 | Sell |
| William %R | -100.00 | Buy |
| CCI(14) | -72.25 | Neutral |
Buy: 4
Sell: 2
Neutral: 1
Summary: Buy
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.052
Sell
|
1.0509
Sell
|
| MA20 |
1.1855
Sell
|
1.1724
Sell
|
| MA50 |
1.4604
Sell
|
1.468
Sell
|
| MA100 |
2.0024
Sell
|
1.7895
Sell
|
| MA200 |
2.1866
Sell
|
2.046
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, VYNE could be considered a Strong Sell, with 17 technical analysis indicators signaling 4 Buy signals, 12 signaling Sell signals and 1 Neutral signals. This might not be a good time to consider opening new positions on VYNE, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 25.56 indicates that VYNE is oversold. This indicates that VYNE price has experienced a significant decline over a specified lookback period, potentially leading to a rebound.
- STOCH (Stochastic Oscillator): The STOCH value of 6.8363 indicates that VYNE is oversold. This indicates that VYNE price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 3.2547 indicates that VYNE is oversold. This suggests that VYNE price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 37.23 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -72.25 indicates that VYNE is still oversold but not to an extreme extent.
Long-term VYNE price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Vyne Therapeutics Inc financial reports and earnings history, Vyne Therapeutics Inc (VYNE) stock could reach $549.11 by 2030, $434.32 by 2040 and $2,540.93 by 2050. See the projected annual prices until 2050 of the Vyne Therapeutics Inc stock below:
- Vyne Therapeutics Inc (VYNE) is expected to reach an average price of $644.88 in 2035, with a high prediction of $640.16 and a low estimate of $636.78. This indicates an $67,782% rise from the last recorded price of $0.95.
- Vyne Therapeutics Inc (VYNE) stock is projected to chart a bullish course in 2040, with an average price target of $402.10, representing an $42,227% surge from its current level. The forecast ranges from a conservative $402.14 to a sky-high $434.32.
- Our analysts predict Vyne Therapeutics Inc (VYNE) to jump 295.88K% by 2045, soaring from $2,831.29 to an average price of $2,811.85, potentially reaching $2,830.24. While $2,831.29 is the low estimate, the potential upside is significant.
- Vyne Therapeutics Inc (VYNE) stock is expected to climb by 2050, reaching an average of $2,570.30, a $270.46K% jump from its current level. However, a wide range of estimates exists, with high and low targets of $2,540.93 and $2,570.09, respectively, highlighting the market's uncertainty.
Vyne Therapeutics Inc Stock (VYNE) Year by Year Forecast
Vyne Therapeutics Inc Stock (VYNE) Price Forecast for 2025
Vyne Therapeutics Inc Stock (VYNE) is expected to reach an average price of $639.09 in 2025, with a high prediction of $1,275.29 and a low estimate of $2.8889. This indicates an +67,173% rise from the last recorded price of $0.95.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| July, 2025 | $29.30 | $6.6218 | $75.15 | +2,984% |
| August, 2025 | $69.87 | $2.8889 | $63.39 | +7,255% |
| September, 2025 | $29.72 | $58.88 | $168.90 | +3,029% |
| October, 2025 | $195.68 | $59.87 | $163.60 | +20,498% |
| November, 2025 | $190.20 | $196.72 | $180.67 | +19,921% |
| December, 2025 | $125.17 | $179.05 | $183.98 | +13,076% |
Vyne Therapeutics Inc Stock (VYNE) Price Forecast for 2026
The predicted value for Vyne Therapeutics Inc (VYNE) in 2026 is set at an average of $159.19. Estimates vary from a peak of $192.79 to a trough of $125.58, indicating an +16,656% surge from the present price of $0.95.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $151.41 | $125.58 | $105.65 | +15,838% |
| February, 2026 | $199.65 | $171.28 | $185.19 | +20,916% |
| March, 2026 | $189.18 | $199.65 | $192.79 | +19,814% |
| April, 2026 | $181.44 | $151.01 | $173.28 | +18,999% |
| May, 2026 | $142.59 | $154.28 | $160.77 | +14,909% |
| June, 2026 | $181.75 | $160.87 | $172.03 | +19,032% |
| July, 2026 | $182.96 | $184.07 | $175.80 | +19,158% |
| August, 2026 | $182.17 | $189.46 | $183.94 | +19,076% |
| September, 2026 | $159.56 | $167.98 | $170.52 | +16,696% |
| October, 2026 | $162.34 | $164.74 | $162.72 | +16,989% |
| November, 2026 | $176.43 | $171.71 | $175.14 | +18,472% |
| December, 2026 | $127.06 | $134.83 | $131.39 | +13,274% |
Vyne Therapeutics Inc Stock (VYNE) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Vyne Therapeutics Inc (VYNE) is $132.59, with a high forecast of $199.07 and a low forecast of $66.11. This indicates an +13,857% increase from the last price of $0.95.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $196.93 | $129.17 | $199.07 | +20,630% |
| February, 2027 | $186.82 | $187.02 | $194.08 | +19,565% |
| March, 2027 | $171.43 | $172.84 | $183.86 | +17,946% |
| April, 2027 | $157.70 | $158.24 | $167.24 | +16,500% |
| May, 2027 | $148.34 | $148.34 | $154.12 | +15,514% |
| June, 2027 | $135.65 | $135.77 | $145.36 | +14,179% |
| July, 2027 | $123.93 | $124.13 | $132.43 | +12,946% |
| August, 2027 | $113.55 | $113.72 | $120.63 | +11,852% |
| September, 2027 | $100.12 | $100.86 | $110.69 | +10,439% |
| October, 2027 | $90.93 | $90.99 | $97.36 | +9,471% |
| November, 2027 | $78.27 | $79.03 | $86.98 | +8,139% |
| December, 2027 | $65.71 | $66.11 | $75.20 | +6,817% |
Vyne Therapeutics Inc Stock (VYNE) Price Forecast for 2028
In 2028, Vyne Therapeutics Inc (VYNE) is projected to reach an average price of $1,288.56, with a high projection of $2,574.35 and a low estimate of $2.7663. This indicates an +135.54K% rise from the last price of $0.95.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $55.40 | $55.45 | $62.75 | +5,732% |
| February, 2028 | $44.57 | $44.76 | $52.61 | +4,592% |
| March, 2028 | $30.52 | $30.63 | $41.45 | +3,112% |
| April, 2028 | $18.68 | $19.55 | $27.60 | +1,866% |
| May, 2028 | $5.4933 | $5.6133 | $15.83 | +478.24% |
| June, 2028 | $631.95 | $2.7663 | $620.61 | +66,421% |
| July, 2028 | $629.42 | $570.11 | $613.50 | +66,154% |
| August, 2028 | $571.16 | $590.60 | $567.57 | +60,023% |
| September, 2028 | $524.89 | $544.33 | $551.09 | +55,151% |
| October, 2028 | $467.27 | $528.83 | $539.82 | +49,086% |
| November, 2028 | $1,368.12 | $223.99 | $2,574.35 | +143.91K% |
| December, 2028 | $1,192.46 | $900.57 | $1,538.85 | +125.42K% |
Vyne Therapeutics Inc Stock (VYNE) Price Forecast for 2029
The 2029 price forecast for Vyne Therapeutics Inc Stock (VYNE) is $645.20 on average, with a high prediction of $1,271.48 and a low estimate of $18.93. This represents an +67,816% increase from the previous price of $0.95.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $678.85 | $523.33 | $1,271.48 | +71,357% |
| February, 2029 | $208.34 | $24.65 | $778.30 | +21,831% |
| March, 2029 | $223.84 | $142.56 | $412.74 | +23,462% |
| April, 2029 | $70.86 | $18.93 | $293.15 | +7,358% |
| May, 2029 | $329.35 | $64.94 | $89.31 | +34,569% |
| June, 2029 | $343.02 | $362.46 | $354.01 | +36,007% |
| July, 2029 | $415.00 | $379.64 | $371.90 | +43,584% |
| August, 2029 | $397.25 | $415.99 | $431.90 | +41,716% |
| September, 2029 | $478.95 | $407.96 | $446.55 | +50,316% |
| October, 2029 | $422.32 | $451.48 | $466.98 | +44,355% |
| November, 2029 | $559.11 | $446.98 | $528.98 | +58,753% |
| December, 2029 | $575.75 | $572.84 | $548.05 | +60,505% |
Vyne Therapeutics Inc Stock (VYNE) Price Forecast for 2030
Vyne Therapeutics Inc Stock (VYNE) is expected to reach an average price of $474.94 in 2030, with a high forecast of $549.11 and a low forecast of $400.76. This signifies an +49,893% surge from the last price of $0.95.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $519.38 | $555.83 | $549.11 | +54,572% |
| February, 2030 | $462.67 | $471.48 | $465.32 | +48,602% |
| March, 2030 | $533.75 | $494.66 | $520.11 | +56,084% |
| April, 2030 | $525.12 | $526.35 | $522.21 | +55,176% |
| May, 2030 | $458.38 | $461.20 | $509.84 | +48,151% |
| June, 2030 | $452.64 | $455.45 | $465.47 | +47,546% |
| July, 2030 | $467.22 | $450.74 | $457.50 | +49,081% |
| August, 2030 | $455.00 | $458.56 | $458.52 | +47,794% |
| September, 2030 | $449.22 | $455.38 | $450.18 | +47,186% |
| October, 2030 | $409.37 | $417.73 | $432.39 | +42,992% |
| November, 2030 | $402.17 | $406.25 | $404.23 | +42,234% |
| December, 2030 | $417.10 | $400.76 | $400.48 | +43,805% |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):